Page 100 - Read Online

Page 198 Ma et al. J Transl Genet Genom 2022;6:179-203 https://dx.doi.org/10.20517/jtgg.2021.48

56. Shin Y. J, Nam W.H, Park S.E, Kim J.H, Kim H.K. Aqueous humor concentrations of vascular endothelial growth factor and pigment
epithelium-derived factor in high myopic patients. Mol Vis 2012;18:2265-70. PubMed PMC
57. Chen W, Song H, Xie S, Han Q, Tang X, Chu Y. Correlation of macular choroidal thickness with concentrations of aqueous vascular
endothelial growth factor in high myopia. Curr Eye Res 2015;40:307-13. DOI PubMed
58. Yamamoto Y, Miyazaki D, Sasaki S, et al. Associations of inflammatory cytokines with choroidal neovascularization in highly
myopic eyes. Retina 2015;35:344-50. DOI PubMed
59. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine
activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem
2009;284:6038-42. DOI PubMed PMC
60. Bianconi V, Sahebkar A, Atkin SL, Pirro M. The regulation and importance of monocyte chemoattractant protein-1. Curr Opin
Hematol 2018;25:44-51. DOI PubMed
61. Leveziel N, Yu Y, Reynolds R, et al. Genetic factors for choroidal neovascularization associated with high myopia. Invest
Ophthalmol Vis Sci 2012;53:5004-9. DOI PubMed PMC
62. Dreismann AK, McClements ME, Barnard AR, et al. Functional expression of complement factor I following AAV-mediated gene
delivery in the retina of mice and human cells. Gene Ther 2021;28:265-76. DOI PubMed PMC
63. Wang Q, Zhao HS, Li L. Association between complement factor I gene polymorphisms and the risk of age-related macular
degeneration: a Meta-analysis of literature. Int J Ophthalmol 2016;9:298-305. DOI PubMed PMC
64. Fraczek LA, Martin BK. Transcriptional control of genes for soluble complement cascade regulatory proteins. Mol Immunol
2010;48:9-13. DOI PubMed
65. Miyake M, Yamashiro K, Nakanishi H, et al. Evaluation of pigment epithelium-derived factor and complement factor I
polymorphisms as a cause of choroidal neovascularization in highly myopic eyes. Invest Ophthalmol Vis Sci 2013;54:4208-12. DOI
PubMed
66. Steele FR, Chader GJ, Johnson LV, Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a
member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A 1993;90:1526-30. DOI PubMed PMC
67. Tombran-tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity.
Exp Eye Res 1991;53:411-4. DOI PubMed
68. Karakousis P. C, John S.K, Behling K.C, et al. Localization of pigment epithelium derived factor (PEDF) in developing and adult
human ocular tissues. Mol Vis 2001;7:154-63.
69. Tombran-tink J, Shivaram S, Chader G, Johnson L, Bok D. Expression, secretion, and age-related downregulation of pigment
epithelium-derived factor, a serpin with neurotrophic activity. J Neurosci 1995;15:4992-5003. PubMed PMC
70. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 2003;4:628-36. DOI PubMed
71. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science
1999;285:245-8. DOI PubMed
72. Cayouette M, Smith SB, Becerra SP, Gravel C. Pigment epithelium-derived factor delays the death of photoreceptors in mouse
models of inherited retinal degenerations. Neurobiol Dis 1999;6:523-32. DOI PubMed
73. Wang X, Liu X, Ren Y, et al. PEDF protects human retinal pigment epithelial cells against oxidative stress via upregulation of UCP2
expression. Mol Med Rep 2019;19:59-74. DOI PubMed PMC
74. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular
proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 2006;281:3604-13. DOI PubMed
75. Renno R. Z, Youssri A.I, Michaud N, Gragoudas E.S, Miller J.W. Expression of pigment epithelium-derived factor in experimental
choroidal neovascularization. Invest Ophthalmol Vis Sci 2002;43:1574-80.
76. Ho TC, Yang YC, Cheng HC, Wu AC, Chen SL, Tsao YP. Pigment epithelium-derived factor protects retinal pigment epithelium
from oxidant-mediated barrier dysfunction. Biochem Biophys Res Commun 2006;342:372-8. DOI PubMed
77. Amano S, Yamagishi S, Inagaki Y, et al. Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and
dysfunction of cultured retinal pericytes. Microvasc Res 2005;69:45-55. DOI PubMed
78. Wang Y, Subramanian P, Shen D, Tuo J, Becerra SP, Chan CC. Pigment epithelium-derived factor reduces apoptosis and pro-
inflammatory cytokine gene expression in a murine model of focal retinal degeneration. ASN Neuro 2013;5:e00126. DOI PubMed
PMC
79. Ruiz-Medrano J, Montero JA, Flores-Moreno I, Arias L, García-Layana A, Ruiz-Moreno JM. Myopic maculopathy: current status
and proposal for a new classification and grading system (ATN). Prog Retin Eye Res 2019;69:80-115. DOI PubMed
80. Ruiz-Medrano J, Flores-Moreno I, Ohno-Matsui K, Cheung CMG, Silva R, Ruiz-Moreno JM. Correlation between atrophy-traction-
neovascularization grade for myopic maculopathy and clinical severity. Retina 2021;41:1867-73. DOI PubMed PMC
81. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia. Ophthalmology 2006;113:2285-91.
DOI PubMed
82. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01%
doses (Atropine for the Treatment of Myopia 2). Ophthalmology 2012;119:347-54. DOI PubMed
83. Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping
atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol 2014;157:451-457.e1. DOI PubMed
84. Chia A, Lu QS, Tan D. Five-Year Clinical Trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01%